Nature Search

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis

Xiaomin Fu
Fanghui Li
Quanli Gao
ResearchOpen Access20 May 2025
Scientific Reports

Volume: 15, P: 1-14
IL-2 regulates tumor-reactive CD8⁺ T cell exhaustion by activating the aryl hydrocarbon receptor

IL-2 is a classic T cell growth factor. Huang and colleagues demonstrate, however, that chronic IL-2 stimulation leads to a new exhaustion pathway that impairs antitumor immune responses.

Yuying Liu
Nannan Zhou
Bo Huang
Research11 Jan 2021
Nature Immunology

Volume: 22, P: 358-369
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Patients with advanced esophageal cancer have poor prognosis and limited treatment options. This randomized, phase II trial compares the efficacy and safety of the anti-PD-1 antibody sintilimab versus chemotherapy in Chinese patients with esophageal squamous cell carcinoma after first-line therapy

Jianming Xu
Yi Li
Christoph Mancao
ResearchOpen Access14 Feb 2022
Nature Communications

Volume: 13, P: 1-12
Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357

Liang Liu
Quanli Gao
Xiubao Ren
ResearchOpen Access19 Oct 2020
Signal Transduction and Targeted Therapy

Volume: 5, P: 1-3
Roles of mTORC1 and mTORC2 in controlling γδ T1 and γδ T17 differentiation and function

Quanli Yang
Xia Liu
Zhinan Yin
Research30 Jan 2020
Cell Death & Differentiation

Volume: 27, P: 2248-2262
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

A subtype of early-stage hepatocellular carcinoma characterized by disrupted cholesterol homeostasis and associated with a poor prognosis responds to treatment with the SOAT1 inhibitor avasimibe in a patient-derived xenograft mouse model.

Ying Jiang
Aihua Sun
Zesong Li
Research27 Feb 2019
Nature

Volume: 567, P: 257-261
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Yuqin Song
Quanli Gao
Jun Zhu
ResearchOpen Access13 Sept 2019
Leukemia

Volume: 34, P: 533-542
Genetic editing and interrogation with Cpf1 and caged truncated pre-tRNA-like crRNA in mammalian cells

Xuhua Zhang
Linping Xu
Yongping Song
ResearchOpen Access10 Jul 2018
Cell Discovery

Volume: 4, P: 1-10
Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma

Quande Lin
Xiyang Liu
Yongping Song
CorrespondenceOpen Access19 Sept 2019
Bone Marrow Transplantation

Volume: 55, P: 1203-1205

Search

Filter By:

Search

Quick links